Combination of calcipotriol and clobetasol propionate as a premixed ointment for the treatment of psoriasis.

Abstract

The treatment of psoriasis requires good compliance, efficacy and low toxicity because of its long-term course and wide distribution. The aim of the study was to compare the efficacy of a once daily application of calcipotriol alone or calcipotriol and a superpotent steroid in a premixed form in patients with psoriasis. The monotherapy group of 32 patients with stable plaque psoriasis received 0.005% calcipotriol alone once daily. The combination group of 29 patients was treated once per day with 0.004% calcipotriol/0.01% clobetasol propionate as a premixed ointment. Eruption score of truncal involvement was evaluated. The combination regimen was more efficacious than the monotherapy as evidenced by (1) more patients with at least 50% reduction in the eruption score after 2 weeks, (2) lower eruption score after 6 weeks and later, and (3) less adverse effects. The combined once-per-day application of 0.004% calcipotriol/0.01% clobetasol propionate as a premixed ointment is a promising regimen for psoriasis.

• Authors: Norito Katoh, Saburo Kishimoto
• Journal: European journal of dermatology : EJD (Eur J Dermatol) 2003 Jul-Aug Vol. 13 Issue 4 Pg. 382-4 ISSN: 1167-1122 [Print] France
• PMID: 12948920 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Dermatologic Agents
• Ointments
• calcipotriene
• Clobetasol
• Calcitriol

Topics

• Administration, Cutaneous
• Calcitriol (administration & dosage, analogs & derivatives)
• Clobetasol (administration & dosage, analogs & derivatives)
• Dermatologic Agents (administration & dosage)
• Drug Therapy, Combination
• Female
• Humans
• Male
• Middle Aged
• Ointments
• Psoriasis (drug therapy, pathology)
• Severity of Illness Index
• Treatment Outcome